

## Nursing Essentials in Castration-Resistant Prostate Cancer: A Plenary Session at the 3rd Annual GLAONS Oncology Care Summit

## Identified Practice Gaps Among Target Audience and Educational Plan to Address Gaps

| Identified Practice Gap   | Reasons Practice Gap Exists  |
|---|--|
| Confusion exists over the optimal therapeutic approach for individual patients with CRPC. | In recent years, the therapeutic armamentarium for CRPC has expanded rapidly to now include novel hormone therapies, second-generation taxanes, radiopharmaceuticals, immunotherapy, and bone-targeted and bone metastasistargeted agents. In the absence of large prospective trials to guide clinical decision making regarding optimal sequences and combinations, numerous relevant factors must be considered, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response. |

## **Learning Objectives**

Upon completion of this activity, participants should be able to:

- Differentiate the safety and efficacy profiles of novel therapies for nonmetastatic and metastatic CRPC
- Outline findings from recent clinical studies on novel combination and sequential treatment strategies for nonmetastatic and metastatic CRPC
- Assess strategies to manage adverse events associated with novel therapies for nonmetastatic and metastatic CRPC

## **Activity Agenda**

- I. Pre-Activity Assessment
- II. CRPC: Scope of the Problem
- III. Audience Polling Icebreaker

Description: Audience polling questions will be used to obtain insights into participants' current understanding of evidence-based care. Results will be shared in real time to set the stage for discussion regarding diagnostic workup, staging, and risk stratification.

- IV. Criteria for Diagnosis, Staging, and Risk Stratification
- V. Current Standards and New Data in the Management of CRPC
  - a. Novel treatment sequences and combinations
  - b. Implications of drug resistance
  - c. Molecular biomarkers
  - d. Disease monitoring
- VI. Case Vignettes With Audience Polling: Nonmetastatic and Metastatic CRPCa

Description: Audience polling questions will be used to obtain insights into participants' understanding of strategies to optimize treatment experiences and set the stage for discussion regarding best practices in supportive care planning.

- a. Dosing and administration
- b. Adherence to therapy
- c. Adverse event management
- d. Patient counseling points
- VII. Future Directions in CRPC Management
- VIII. Review of Key Learning Takeaways/Participant Q&As
- IX. Post-Activity Assessment
- X. 4-Week Clinical Pearls Follow-Up Email